-
公开(公告)号：US5824519A
公开(公告)日：1998-10-20
申请号：US554369
申请日：1995-11-08
Applicant: James S. Norris , Gary A. Clawson
Inventor： James S. Norris , Gary A. Clawson
IPC: A01K67/027 , A61K31/00 , A61K38/00 , A61K48/00 , A61P31/00 , A61P31/12 , A61P35/00 , A61P43/00 , C12N5/10 , C12N9/00 , C12N15/09 , C12N15/113 , C12N15/88 , C12P19/34 , C07H21/02 , C12N15/11
CPC classification number: C12N15/113 , C12N15/1131 , C12N15/1137 , C12N15/88 , C12Y207/07006 , A01K2217/05 , A01K2267/03 , A61K38/00 , A61K48/00 , C12N2310/111 , C12N2310/121 , C12N2310/127 , C12N2799/021
Abstract: The invention provides tissue-specific and target RNA-specific ribozymes. These ribozymes can be used to destroy target-specific neoplasms and to treat viral infections, among other uses. The ribozymes of the present invention comprise a 5' autocatalytically cleaving ribozyme sequence, a catalytic ribozyme comprising a target RNA-specific binding site and a 3' autocatalytically cleaving ribozyme. The invention also provides nucleic acids which encode the ribozymes of the invention. These nucleic acids can be used to express the ribozymes of the invention at the selected site. Methods of treating disease by administering the ribozymes are provided.
Abstract translation: 本发明提供组织特异性和靶RNA特异性核酶。 这些核酶可用于破坏靶特异性肿瘤并治疗病毒感染以及其他用途。 本发明的核酶包含5'自动催化裂解核酶序列，包含靶RNA特异性结合位点和3'自动催化裂解核酶的催化核酶。 本发明还提供了编码本发明的核酶的核酸。 这些核酸可用于在所选择的位点表达本发明的核酶。 提供了通过施用核酶来治疗疾病的方法。
-
公开(公告)号：US20240301457A1
公开(公告)日：2024-09-12
申请号：US18569914
申请日：2022-06-13
Applicant: Primrose Bio, Inc.
Inventor： Daniel OLSON , Dongxin Karen XU , Sabrina BAFFERT , Helge ZIELER
CPC classification number: C12P19/34 , C12N9/1247 , C12N9/1252 , C12Y207/07006 , C12Y207/07007
Abstract: The present disclosure describes compositions and methods useful for the template independent enzymatic synthesis of nucleic acids.
-
公开(公告)号：US20240150770A1
公开(公告)日：2024-05-09
申请号：US18509899
申请日：2023-11-15
Applicant: New England Biolabs, Inc.
Inventor： Nathan Tanner , Jennifer Ong , Esta Slayton , Lisa L. Maduzia , Salvatore V. Russello
IPC: C12N15/113 , C12N9/12 , C12N15/10 , C12Q1/6848
CPC classification number: C12N15/1137 , C12N9/1247 , C12N9/1276 , C12N15/1003 , C12Q1/6848 , C12N9/58 , C12N2310/16 , C12Y207/07006 , C12Y207/07049
Abstract: Compositions, methods and kits are provided that include an inhibitory oligonucleotide RNase inhibitor capable of inhibiting one or more types of RNase that coexist with biological samples or are introduced in the laboratory, thereby protecting RNA in the sample from degradation. More than one type of oligonucleotide RNase inhibitor may be combined in a mixture to inhibit a plurality of different RNases. Single oligonucleotides were identified to have inhibitory activity for a plurality of different RNases. The RNase oligonucleotide inhibitor may be immobilized on beads or other surface. It may be stored in a lyophilized form or in solution.
-
公开(公告)号：US11959105B2
公开(公告)日：2024-04-16
申请号：US16914195
申请日：2020-06-26
Applicant: Quantum-Si Incorporated
Inventor： Brian Reed , Manjula Pandey
IPC: C12N9/12 , C12N1/21 , C12N11/00 , C12P19/34 , C12Q1/6806
CPC classification number: C12N9/1247 , C12N11/00 , C12P19/34 , C12Q1/6806 , C12Y207/07006 , C07K2319/21
Abstract: Compositions comprising modified recombinant polymerizing enzymes are provided, along with nucleic acid molecules encoding the modified polymerizing enzymes. In some aspects, methods of using such polymerizing enzymes to synthesize a nucleic acid molecule or to sequence a nucleic acid template are provided.
-
65.发明公开公开(公告)号：US20240093196A1
公开(公告)日：2024-03-21
申请号：US18522923
申请日：2023-11-29
Applicant: DNA TWOPOINTO INC.
Inventor： Jeremy MINSHULL , Maggie LEE
IPC: C12N15/113 , C12N9/12 , C12N15/86 , C12N15/90
CPC classification number: C12N15/113 , C12N9/1241 , C12N9/1247 , C12N15/1137 , C12N15/86 , C12N15/90 , C12N2310/141 , C12N2310/3519 , C12N2310/51 , C12N2310/531 , C12N2800/90 , C12Y207/07006 , C12Y603/01002
Abstract: The present invention provides methods and compositions for stable genetic modification of cultured mammalian cells. The genetic modifications can be used to produce cultured mammalian cells for therapeutic or diagnostic purposes.
-
Patent Agency Ranking
公开(公告)号：US20240043892A1
公开(公告)日：2024-02-08
申请号：US18345379
申请日：2023-06-30
Applicant: Arcturus Therapeutics, Inc.
Inventor： Maher ALAYYOUBI , Kyoung-Joo Jenny CHOI , Timothy Wayne LUGER, II
CPC classification number: C12P19/34 , C12N9/1007 , C12Y201/01 , C12N9/1247 , C12Y207/07006
Abstract: Disclosed herein are methods of producing transcribed RNA product with increased yield and reduced dsRNA impurities.
-
公开(公告)号：US11884950B2
公开(公告)日：2024-01-30
申请号：US17143318
申请日：2021-01-07
Applicant: Oxford Nanopore Technologies PLC
Inventor： John Milton , Sobia Nayyar , Jan Riedl , Ryosuke Ogaki
CPC classification number: C12P19/34 , B01J19/0046 , C12N9/1247 , C12N9/1252 , C12N15/1093 , C12Y207/07006 , C12Y207/07007 , B01J2219/00596 , B01J2219/00608 , B01J2219/00722
Abstract: The invention relates to new methods for synthesising polynucleotide molecules according to a predefined nucleotide sequence. The invention also relates to methods for the assembly of synthetic polynucleotides following synthesis, as well as systems and kits for performing the synthesis and/or assembly methods.
-
公开(公告)号：US11845936B2
公开(公告)日：2023-12-19
申请号：US17519546
申请日：2021-11-04
Applicant: DNA TWOPOINTO INC.
Inventor： Jeremy Minshull , Maggie Lee
IPC: C12N15/113 , C12N9/12 , C12N15/90 , C12N15/86
CPC classification number: C12N15/113 , C12N9/1241 , C12N9/1247 , C12N15/1137 , C12N15/86 , C12N15/90 , C12N2310/141 , C12N2310/3519 , C12N2310/51 , C12N2310/531 , C12N2800/90 , C12Y207/07006 , C12Y603/01002
Abstract: The present invention provides methods and compositions for stable genetic modification of cultured mammalian cells. The genetic modifications can be used to produce cultured mammalian cells for therapeutic or diagnostic purposes.
-
公开(公告)号：US11773422B2
公开(公告)日：2023-10-03
申请号：US16543433
申请日：2019-08-16
Applicant: MICROSOFT TECHNOLOGY LICENSING, LLC
Inventor： Bichlien Hoang Nguyen
IPC: C12P19/36 , B01J19/00 , C12Q1/6874 , C12P19/34
CPC classification number: C12P19/36 , B01J19/0046 , C12Q1/6874 , C12Y207/07031 , B01J2219/00711 , B01J2219/00713 , C12P19/34 , C12Y207/07006
Abstract: Polynucleotide synthesis performed with a substrate independent polymerase such as terminal deoxynucleotidyl transferase (TdT) is regulated by controlling the oxidation state of a metal cofactor. The oxidation state of the metal cofactor is changed to +2, thus activating the polymerase, by applying a voltage with electrodes or by introducing a chemical redox reagent. Addressable polynucleotide synthesis creates polynucleotides with different arbitrary sequences through use of spatial control of cofactor oxidation states to add nucleotides only at selected locations on an array. Control of metal oxidation states is regulated by selective activation of a microelectrode array, controlled addition of redox reagents to specific locations on the array, or controlled activation of photocatalysts at specific locations on the array. Scavengers in solution prevent cofactors distant from the selected locations from catalyzing polymerase activity and thereby maintain the localized effect of polymerase activation.
-
公开(公告)号：US20230174957A1
公开(公告)日：2023-06-08
申请号：US17924637
申请日：2021-05-11
Applicant: Thermo Fisher Scientific Baltics UAB
Inventor： Arvydas Lubys , Zana Kapustina , Aiste Jaspone
CPC classification number: C12N9/1247 , C12P19/34 , C12Y207/07006
Abstract: This application relates to mutant polymerases. This application discloses mutant phage-type RNA polymerases, such as a mutant T7, SP6, and T3 RNA polymerase, may use 2′-modified nucleoside triphosphates or deoxynucleotide triphosphates as substrates. Methods for producing nucleic acid molecules using these mutant polymerases are also disclosed.
-
-
-
-
-
-
-
-
-
Search Results
120
records
(took 0.016 seconds)
